ABSTRACT
In the response strategy against the Covid-19 pandemic, Cameroon has used to date, two types of vaccine namely: Sinopharm, Covishield/AstraZeneca. The objective of this study is to determine the KAP and the epidemiological profile of Muslim faithful receiving the Covid-19 vaccine at Mosque Biyem-Assi, Yaounde-Cameroon. Data on COVID-19, vaccination, and clinical characteristics were collected. A total of 58 participants took part in the first survey and equally received their first dose of the COVID-19 vaccine of their choice. The majority of the participants were females (n =32, 55.2%), 37.9% were 50 years and over and 43.1% had a university degree. Overall score was 78.41% for knowledge, 92.8% for perceptions and 48.3% for practices. Despite the availability and gratuity only half of the Participants reported to have carried out their COVID-19 test ever since the pandemic started. Out of 40 (69.0) participants who have heard stories concerning the vaccines, 39.7% suggested that they COVID-19 vaccines can protect us from the disease. Also, out of the 58 participants who received their first dose of the anti-COVID-19 vaccine, 36 of them came for their second shot amounting for a 62% complete vaccination rate. Headache, pain and heaviness of the injected arm were the most frequently reported side effects following participants first shot. The mobile based strategy could be the best solution to increase vaccine uptake in Cameroon.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of the National Ethics Committee waived ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
